SPECTRUM PHARMACEUTICALS INC (SPPI) Stock Analyst Ratings
USA - NASDAQ:SPPI - US84763A1088 - Common Stock
1.03 USD
0 (0%)
1.04 USD
+0.01 (+0.97%)
ChartMill assigns a Buy % Consensus number of 50% to SPPI. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.29. This target is 24.78% above the current price.
SPPI was analyzed by 10 analysts. The buy percentage consensus is at 50. So analysts seem to be rather neutral about SPPI.
In the previous month the buy percentage consensus was at a similar level.
SPPI was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-05-26 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2023-05-15 | Jefferies | Downgrade | Buy -> Hold |
| 2023-04-26 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2023-04-26 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-02-06 | JMP Securities | Reiterate | Market Outperform |
| 2023-02-03 | Cantor Fitzgerald | Maintains | Neutral |
| 2023-02-01 | JMP Securities | Reiterate | Market Outperform |
| 2023-01-31 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-28 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-16 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2022-09-23 | HC Wainwright & Co. | Maintains | Buy |
| 2022-09-20 | HC Wainwright & Co. | Maintains | Buy |
| 2022-09-12 | HC Wainwright & Co. | Maintains | Buy |
SPECTRUM PHARMACEUTICALS INC / SPPI FAQ
What is the average price target for SPECTRUM PHARMACEUTICALS INC (SPPI) stock?
10 analysts have analysed SPPI and the average price target is 1.29 USD. This implies a price increase of 24.78% is expected in the next year compared to the current price of 1.03.
What is the consensus rating for SPECTRUM PHARMACEUTICALS INC (SPPI) stock?
The consensus rating for SPECTRUM PHARMACEUTICALS INC (SPPI) is 50 / 100 . This indicates that analysts generally have a neutral outlook on the stock.